Julie C. Smith

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

A phase III trial comparing an anionic phospholipid-based cream and aloe vera-based gel in the prevention of radiation dermatitis in pediatric patients

Thomas E. Merchant, Christina Bosley, Julie C. Smith et al. · Radiation Oncology · 2007 · 54 citations · Full text

Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium

Ajay K. Gopal, Oliver W. Press, Andrei R. Shustov et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2010 · 53 citations · Full text

Immunology, Immunotherapy, Hematological Malignancy +16

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Lynn Symonds, Hannah M. Linden, Vijayakrishna K. Gadi et al. · Clinical Breast Cancer · 2018 · 36 citations

Breast Oncology, Oncology, Pharmacology +7

Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trial

Philip Robinson, Michael S. Schechter, Peter D. Sly et al. · Pediatric Pulmonology · 2012 · 28 citations